Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center

Read as PDF

Lund, Sweden, 22th of June 2017 - Xintela AB (publ) announces that the company is a partner in a project, financed by Vinnova and Vetenskapsrådet, to establish an international research center for effective production and development of Advanced Therapy Medicinal Products in cell and gene therapy. The project has been granted 48 MSEK in financing and will have a duration of six years.

As one of the founders responsible for the establishment of the international research center, named Centre for Advanced Medical Products (CAMP), Xintela will interact with, among others, AstraZeneca, GE Healthcare, Pfizer, all Swedish universities as well as several health care regions and research institutions. The goal is to gain international recognition.

“It is gratifying that the Swedish government, Vinnova and Vetenskapsrådet acknowledge the huge potential of cell and gene therapy and the strong position that Sweden has in this research field. Xintela is one of the companies in Sweden with large development potential in cell therapy, which makes us a natural partner for this project. Vi expect this initiative to support our own development projects as well as the research field in general”, says Xintelas CEO Evy Lundgren-Åkerlund.

Initially, Xintela will contribute as an advisor for the development of the center. Over time the company expects to benefit from the research and development and the knowledge that the center will facilitate, as well as contacts with other internationally leading companies and researchers.

The initiative to establish a research center is included in an eight-year research program for biologics totaling 320 million SEK, which is a part of the Swedish government’s strategic cooperation program in life science. The aim is for Sweden to be a leader in the development of this field.

About CAMP - Centre for Advanced Medical Products
CAMP aims to establish itself as an internationally recognized center focusing on industry growth and small and medium size enterprises, clinical practice, research and education, advanced production technology and a prominent innovation and business environment. In the longer term, the center can help attract investment from the global life science industry, including pharmaceuticals, biotech, medical technology and service industries.

For more information on the initiative, read the press release from Vinnova (in Swedish) that was published on the 19th of June: http://www.mynewsdesk.com/se/vinnova/pressreleases/stor-satsning-paa-forskningscentrum-ska-goera-sverige-ledande-inom-biologiska-laekemedel-2024172


Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village 223 81 Lund
www.xintela.se

For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se

About Xintela
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The key to Xintela's business is the Company's patented marker technology, XINMARK®. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces.  The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK®-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 22th of June 2017, at 10.00 CET.

Archive

Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

November 13, 2017
Xintela raises 17 million SEK in debt and equity
October 17, 2017
Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons.
September 11, 2017
Xintela building own GMP-facility for stem cell production
July 17, 2017
Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
June 22, 2017
Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center
May 22, 2017
Xintela signs Memorandum of Understanding with the leading European cell therapy company, CO.DON
May 9, 2017
Xintela: Keld Sondergaard nominated as new board member
March 21, 2017
Xintela announces today that Thomas Areschoug has been recruited to the business development team......
February 8, 2017
(In Swedish) Xintela: Insynspersoner och huvudägare avser nyttja teckningsoptioner av serie TO1
January 20, 2017
Xintela reports positive preclinical results in cancer project
January 4, 2017
Xintela´s stem cells show positive treatment effects on cartilage damage in horse study
December 22, 2016
Xintela reports positive results from completed horse study
September 12, 2016
Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016.
August 22, 2016
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation.
June 23, 2016
Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor
June 1, 2016
Xintela strengthens its organisation wih the appointment of Caroline Ehrencrona as Director Clincial Development and Regulatory Affairs
April 25, 2016
Xintela initiates a study on the treatment of cartilage damage in horses in the USA.
March 16, 2016
Xintela's press releases are currently only published in Swedish. Please contact us if you have further questions.
September 28, 2017
‍Strategic decisions that builds significant value
July 19, 2017
Focusing on Stem Cell Production and Preparations for Clinical Trials
May 16, 2017
On the 21st March 2017, Xintela reported that it was strengthening its Business Development team...
April 5, 2017
A word from the CEO
April 5, 2017
The subscription period for shares supported by warrants has started
December 29, 2016
A Year of Significant Progress
December 14, 2016
Glioblastoma—Xintela's Focus in the Cancer Arena
November 8, 2016
Starting the Autumn with an increased focus on Xintela’s commercial development
October 19, 2016
Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
August 11, 2016
Confidence in the future with a strong organisation
August 11, 2016
Welcome to Xintela's newsletter
February 22, 2018
Year-End Report 2017
November 23, 2017
Q3 January - September 2017
February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 16, 2016

Investor presentation from Lund - Jan 27

March 15, 2016

Interview with Xintelas CEO

March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
March 17, 2016
Future financial analyses of Xintela will be published here.
Top